BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29340706)

  • 1. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
    Kaneko T; Konno H; Baba M; Tanaka T; Nakamura S
    Cancer Sci; 2003 Jan; 94(1):43-9. PubMed ID: 12708473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response.
    Setiawan L; Setiabudy R; Kresno SB; Sutandyo N; Syahruddin E; Jovianti F; Nadliroh S; Mubarika S; Setiabudy R; Siregar NC
    Cancer Biomark; 2024; 39(2):137-153. PubMed ID: 38073374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
    Mahmood N; Mihalcioiu C; Rabbani SA
    Front Oncol; 2018; 8():24. PubMed ID: 29484286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19.
    Yatsenko T; Rios R; Nogueira T; Takahashi S; Tabe Y; Naito T; Takahashi K; Hattori K; Heissig B
    Front Immunol; 2023; 14():1299792. PubMed ID: 38313435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma.
    Wang S; Jiang L; Han Y; Chew SH; Ohara Y; Akatsuka S; Weng L; Kawaguchi K; Fukui T; Sekido Y; Yokoi K; Toyokuni S
    Oncotarget; 2016 Oct; 7(43):69565-69578. PubMed ID: 27602956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy.
    Richlitzki C; Wiesweg M; Metzenmacher M; Guberina N; Pöttgen C; Hautzel H; Eberhardt WEE; Darwiche K; Theegarten D; Aigner C; Bölükbas S; Schuler M; Stuschke M; Guberina M
    Sci Rep; 2024 Jun; 14(1):13765. PubMed ID: 38877146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. uPA-PAI-1 heteromerization promotes breast cancer progression by attracting tumorigenic neutrophils.
    Uhl B; A Mittmann L; Dominik J; Hennel R; Smiljanov B; Haring F; B Schaubächer J; Braun C; Padovan L; Pick R; Canis M; Schulz C; Mack M; Gutjahr E; Sinn P; Heil J; Steiger K; Kanse SM; Weichert W; Sperandio M; Lauber K; Krombach F; Reichel CA
    EMBO Mol Med; 2021 Jun; 13(6):e13110. PubMed ID: 33998175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer.
    Memarzadeh S; Kozak KR; Chang L; Natarajan S; Shintaku P; Reddy ST; Farias-Eisner R
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10647-52. PubMed ID: 12130664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case control study on the structural equation model of the mechanism of coagulation and fibrinolysis imbalance in chronic schistosomiasis.
    Le A; Zhang L; Liu W; Li X; Ren J; Ning A
    Medicine (Baltimore); 2017 Feb; 96(7):e6116. PubMed ID: 28207534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer.
    Niki M; Yokoi T; Kurata T; Nomura S
    Lung Cancer (Auckl); 2017; 8():91-99. PubMed ID: 28814907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the diagnostic value of CEA combined with OPN or DKK1 in non-small cell lung cancer.
    Sun J; Chen X; Wang Y
    Oncol Lett; 2020 Sep; 20(3):3046-3052. PubMed ID: 32782622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of urokinase-type plasminogen activator in healthy dogs and oncologic canine patients.
    Ramos SC; de Matos AJ; Ribeiro JN; Leite-Martins LR; Ferreira RRF; Viegas I; Santos AA
    Vet World; 2017 Aug; 10(8):918-923. PubMed ID: 28919683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo anti-tumor effect of Trichobakin fused with urokinase-type plasminogen activator ATF-TBK.
    Pham DD; Pham TH; Bui TH; Britikova EV; Britikov VV; Bocharov EV; Usanov SA; Phan VC; Le TBT
    Mol Biol Rep; 2024 Jan; 51(1):130. PubMed ID: 38236367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.
    Meng S; Tripathy D; Shete S; Ashfaq R; Saboorian H; Haley B; Frenkel E; Euhus D; Leitch M; Osborne C; Clifford E; Perkins S; Beitsch P; Khan A; Morrison L; Herlyn D; Terstappen LW; Lane N; Wang J; Uhr J
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17361-5. PubMed ID: 17079488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteopontin in cancer.
    Kumari A; Kashyap D; Garg VK
    Adv Clin Chem; 2024; 118():87-110. PubMed ID: 38280808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial.
    Prasmickaite L; Berge G; Bettum IJ; Aamdal S; Hansson J; Bastholt L; Øijordsbakken M; Boye K; Mælandsmo GM
    Cancer Immunol Immunother; 2015 Jun; 64(6):769-76. PubMed ID: 25832001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum uPAR as Biomarker in Breast Cancer Recurrence: A Mathematical Model.
    Hao W; Friedman A
    PLoS One; 2016; 11(4):e0153508. PubMed ID: 27078836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Significance of Serum Inflammatory Response Markers in Newly Diagnosed Non-Small Cell Lung Cancer before Chemoirradiation.
    Tolia M; Tsoukalas N; Kyrgias G; Mosa E; Maras A; Kokakis I; Liakouli Z; Kouvaris JR; Liaskonis K; Charalampakis N; Pistevou-Gombaki K; Kelekis N; Kouloulias V
    Biomed Res Int; 2015; 2015():485732. PubMed ID: 26339617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and
    Wong JPC; Wei R; Lyu P; Tong OLH; Zhang SD; Wen Q; Yuen HF; El-Tanani M; Kwok HF
    Int J Biol Sci; 2017; 13(11):1373-1386. PubMed ID: 29209142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.